Immune Cells Adapt Inefficiently in Patients with Uncontrolled HIV
By LabMedica International staff writers Posted on 28 Mar 2016 |
Antibodies derived from a type of immune cell found in unusually high numbers in human immunodeficiency virus (HIV)-infected individuals with chronically uncontrolled virus levels are less effective at neutralizing HIV than antibodies derived from a different type of immune cell more common in people without HIV.
HIV infection leads to numerous immunologic abnormalities, especially in individuals whose viremia is not well controlled, either naturally or by antiretroviral therapy (ART). B cells are not direct targets for HIV replication; however, direct and indirect consequences of viral replication such as immune activation and lymphopenia lead to numerous B cell abnormalities over the course of infection.
Scientists at the US National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and their colleagues collected serum and/or leukapheresis products from 25 chronically infected HIV-viremic individuals. The donors were not taking antiretroviral drugs to suppress the level of HIV in their blood, or viral load, at the time of the study. Like many individuals with persistent levels of HIV, the donors' blood samples had abnormally high numbers of immune cells called tissue-like memory (TLM) B cells, compared with resting memory (RM) B cells, which account for the majority of memory B cells in people without HIV.
Peripheral blood mononuclear cells (PBMCs) were obtained by density-gradient centrifugation. Mature CD10-B cells were isolated from PBMCs by negative magnetic bead–based selection using a B cell enrichment cocktail that was supplemented with tetrameric anti-CD10 monoclonal antibodies (mAb) (STEMCELL Technologies; Vancouver, BC, Canada). Immunophenotyping to identify suitable subjects for sorting was performed using the following anti-human mAbs. Fluorescent activated cell sorting (FACS) analyses were performed on a FACSCanto II flow cytometer and sorting of B cell populations and of single HIV-specific B cells into 96-well polymerase chain reaction (PCR) plates was performed on a modified 3-laser FACSAria instrument (BD Biosciences; San Jose, CA, USA).
Generally, as B cells divide in response to a pathogen like HIV, genes that produce infection-fighting antibodies mutate, and descendant cells producing the most effective antibodies predominate. Despite the fact that TLM B cells generally divided more frequently than their RM counterparts, the scientists found that the antibodies derived from TLM B cells showed genetic evidence of fewer adaptive mutations than those derived from RM B cells. In turn, these antibodies were less likely to effectively neutralize HIV than those derived from RM B cells. The RM B cells, in contrast, showed evidence of generating antibodies with more helpful mutations.
The authors concluded that nonconventional TLM B cells overrepresented in the peripheral blood of chronically infected HIV-viremic individuals show reduced affinity maturation compared with their clonally related conventional RM counterparts, despite evidence of having undergone more cell divisions. The study was published on March 17, 2016, in the journal JCI Insight.
Related Links:
US National Institute of Allergy and Infectious Diseases
STEMCELL Technologies
BD Biosciences
HIV infection leads to numerous immunologic abnormalities, especially in individuals whose viremia is not well controlled, either naturally or by antiretroviral therapy (ART). B cells are not direct targets for HIV replication; however, direct and indirect consequences of viral replication such as immune activation and lymphopenia lead to numerous B cell abnormalities over the course of infection.
Scientists at the US National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and their colleagues collected serum and/or leukapheresis products from 25 chronically infected HIV-viremic individuals. The donors were not taking antiretroviral drugs to suppress the level of HIV in their blood, or viral load, at the time of the study. Like many individuals with persistent levels of HIV, the donors' blood samples had abnormally high numbers of immune cells called tissue-like memory (TLM) B cells, compared with resting memory (RM) B cells, which account for the majority of memory B cells in people without HIV.
Peripheral blood mononuclear cells (PBMCs) were obtained by density-gradient centrifugation. Mature CD10-B cells were isolated from PBMCs by negative magnetic bead–based selection using a B cell enrichment cocktail that was supplemented with tetrameric anti-CD10 monoclonal antibodies (mAb) (STEMCELL Technologies; Vancouver, BC, Canada). Immunophenotyping to identify suitable subjects for sorting was performed using the following anti-human mAbs. Fluorescent activated cell sorting (FACS) analyses were performed on a FACSCanto II flow cytometer and sorting of B cell populations and of single HIV-specific B cells into 96-well polymerase chain reaction (PCR) plates was performed on a modified 3-laser FACSAria instrument (BD Biosciences; San Jose, CA, USA).
Generally, as B cells divide in response to a pathogen like HIV, genes that produce infection-fighting antibodies mutate, and descendant cells producing the most effective antibodies predominate. Despite the fact that TLM B cells generally divided more frequently than their RM counterparts, the scientists found that the antibodies derived from TLM B cells showed genetic evidence of fewer adaptive mutations than those derived from RM B cells. In turn, these antibodies were less likely to effectively neutralize HIV than those derived from RM B cells. The RM B cells, in contrast, showed evidence of generating antibodies with more helpful mutations.
The authors concluded that nonconventional TLM B cells overrepresented in the peripheral blood of chronically infected HIV-viremic individuals show reduced affinity maturation compared with their clonally related conventional RM counterparts, despite evidence of having undergone more cell divisions. The study was published on March 17, 2016, in the journal JCI Insight.
Related Links:
US National Institute of Allergy and Infectious Diseases
STEMCELL Technologies
BD Biosciences
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form